Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
The Autopian on MSN
Some Geniuses Are Installing Jeep Gladiator Parts On Old Jeep Comanches
When the Jeep Gladiator debuted at the 2018 Los Angeles Auto Show, it sparked a renewed interest in the Jeep pickup that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback